Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

armagen.com

Founded Year

2001

Stage

Acquired | Acquired

Total Raised

$27M

About ArmaGen

ArmaGen is a privately held, clinical-stage biotechnology company focused on developing therapies for severe neurological disorders. The company is advancing therapies for the treatment of currently unaddressed neurological complications of lysosomal storage disorders (LSDs), as well as neurodegenerative diseases such as Alzheimer's and Parkinson's.On March 27th, 2020, the firm was acquired by JCR Pharmaceuticals. The terms of the transaction were not disclosed.

ArmaGen Headquarters Location

26679 Agoura Road Suite 100

Calabasas, California, 91302,

United States

818-252-8200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ArmaGen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ArmaGen is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

ArmaGen Patents

ArmaGen has filed 33 patents.

The 3 most popular patent topics include:

  • Rare diseases
  • Autosomal recessive disorders
  • Peripherally selective drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/9/2015

10/26/2021

Monoclonal antibodies, Immune system, Immunology, Clusters of differentiation, Peripherally selective drugs

Grant

Application Date

1/9/2015

Grant Date

10/26/2021

Title

Related Topics

Monoclonal antibodies, Immune system, Immunology, Clusters of differentiation, Peripherally selective drugs

Status

Grant

Latest ArmaGen News

Mucopolysaccharidosis Treatment Market to Record a CAGR of 5.10%, ArmaGen Inc., Sangamo Therapeutics and Hamilton Storage Technologies Among Key Vendors – Market.us

Sep 12, 2022

Search jobs 12-Sep-2022 Mucopolysaccharidosis Treatment Market to Record a CAGR of 5.10%, ArmaGen Inc., Sangamo Therapeutics and Hamilton Storage Technologies Among Key Vendors – Market.us Pune, Maharashtra, India, September 12 2022 (Wiredrelease) Prudour Pvt. Ltd –:Mucopolysaccharidosis (MPS) is a rare, progressive genetic disorder that causes severe damage to the body’s tissues and organs. There is no cure for MPS, but treatment can help manage the symptoms and slow the progression of the disease. Early diagnosis and treatment are vital to improve the quality of life for people with MPS. This article will provide an overview of MPS and its treatment. The Worldwide Mucopolysaccharidosis Treatment Market is estimated to be worth around USD 2.340 Bn in 2022 and this market is projected to grow at a robust CAGR of 5.10% between 2022 and 2029, reaching a valuation of USD 3.40 Bn by 2029. Mucopolysaccharidosis (MPS) is a rare disease that affects children. There is no cure for MPS, but treatments are available to manage the symptoms and slow the progression of the disease. The global mucopolysaccharidosis treatment market is expected to grow significantly during the forecast period (2022-2032). This growth is primarily due to the increasing prevalence of MPS, availability of new treatments, and government initiatives to raise awareness about MPS. Mucopolysaccharidosis (MPS) Treatment Market: Restraints High cost of therapeutics coupled with poor diagnosis are expected to hinder growth of the global mucopolysaccharidosis (MPS) treatment market during the forecast period. Vimizin (elosulfase-alfa) is a treatment for MPS IV (Morquio Syndrome). It was launched in the market at a cost of US$ 380,000 per year. Patients in emerging economies like India can’t afford this treatment because of the high price. Another key limiting factor is the delay associated with the diagnosis of mucopolysaccharidosis. For instance, according to the study published in 2018, in the Orphanet Journal of Rare Diseases, there is a failure in diagnosis of the two ultra-orphan diseases of mucopolysaccharidosis type I and mucopolysaccharidosis type III. For Right Perspective & Competitive Insights on Mucopolysaccharidosis Treatment Market, Request for a Sample PDF: https://market.us/report/mucopolysaccharidosis-treatment-market/request-sample/ Key Market Players included in the report: BioMarin Pharmaceutical Inc. Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe) Asia-Pacific (China, Korea, India, Southeast Asia, and Australia) South America (Brazil, Argentina, Colombia, and Rest of South America) Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa) To turn massive challenges into meaningful change, Make an Inquiry of the report@  https://market.us/report/mucopolysaccharidosis-treatment-market/#inquiry    Who will all get benefits from Global Mucopolysaccharidosis Treatment market research report? – Product managers, Mucopolysaccharidosis Treatment industry administrator, chief administrative officers of the industries. – Scientists, Mucopolysaccharidosis Treatment investigators, research analysts, and laboratory expertise. – Universities, students, interns, professors and various other academic organization interested in Mucopolysaccharidosis Treatment market. – Writer, journalists, editors, reporter and webmasters get to know about Mucopolysaccharidosis Treatment. – Private/governmental institutes, project managers associate in Mucopolysaccharidosis Treatment industry. – Current or forthcoming Mucopolysaccharidosis Treatment market players. Frequently Asked Questions What are the growth estimates for the global mucopolysaccharidosis (MPS) treatment market till 2032? What will be the compound annual growth rate (CAGR) for the global mucopolysaccharidosis (MPS) treatment market during the forecast period? What is the current mucopolysaccharidosis treatment market valuation? What is the mucopolysaccharidosis treatment market demand outlook? At what rate did the mucopolysaccharidosis treatment market grow between 2015 and 2021? What are the key trends shaping the mucopolysaccharidosis treatment market? Who are the leading players in mucopolysaccharidosis treatment market? What are the key factors hampering growth of the market? MORE RELATED REPORTS FROM OUR DATABASE :

  • When was ArmaGen founded?

    ArmaGen was founded in 2001.

  • Where is ArmaGen's headquarters?

    ArmaGen's headquarters is located at 26679 Agoura Road, Calabasas.

  • What is ArmaGen's latest funding round?

    ArmaGen's latest funding round is Acquired.

  • How much did ArmaGen raise?

    ArmaGen raised a total of $27M.

  • Who are the investors of ArmaGen?

    Investors of ArmaGen include JCR Pharmaceuticals, Takeda Ventures, Mitsui & Co. Global Investment, Shire Strategic Investment Group and Boehringer Ingelheim.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.